WO2020144382A3 - Cellules stromales neonatales felines et leurs utilisations - Google Patents

Cellules stromales neonatales felines et leurs utilisations Download PDF

Info

Publication number
WO2020144382A3
WO2020144382A3 PCT/EP2020/050721 EP2020050721W WO2020144382A3 WO 2020144382 A3 WO2020144382 A3 WO 2020144382A3 EP 2020050721 W EP2020050721 W EP 2020050721W WO 2020144382 A3 WO2020144382 A3 WO 2020144382A3
Authority
WO
WIPO (PCT)
Prior art keywords
neonatal
stromal cells
felines
cells derived
population
Prior art date
Application number
PCT/EP2020/050721
Other languages
English (en)
Other versions
WO2020144382A2 (fr
Inventor
Stéphane MADDENS
Nathalie SAULNIER
Marine FEBRE
Original Assignee
Vetbiobank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vetbiobank filed Critical Vetbiobank
Priority to US17/422,010 priority Critical patent/US20220280570A1/en
Priority to EP20700707.1A priority patent/EP3908295A2/fr
Publication of WO2020144382A2 publication Critical patent/WO2020144382A2/fr
Publication of WO2020144382A3 publication Critical patent/WO2020144382A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une population de cellules stromales néonatales (CSN) félines et un véhicule pharmaceutiquement acceptable, en particulier une solution comprenant un cryoprotecteur. L'invention porte également sur une population de CSN ou une composition pharmaceutique comprenant une telle population pour une utilisation en thérapie cellulaire, en particulier en thérapie cellulaire allogénique, et plus particulièrement pour le traitement de stomatites félines. L'invention concerne également une solution injectable prête à l'emploi comprenant des CSN félines.
PCT/EP2020/050721 2019-01-11 2020-01-13 Cellules stromales neonatales felines et leurs utilisations WO2020144382A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/422,010 US20220280570A1 (en) 2019-01-11 2020-01-13 Stromal cells derived from neonatal felines and uses thereof
EP20700707.1A EP3908295A2 (fr) 2019-01-11 2020-01-13 Cellules stromales neonatales felines et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1900284 2019-01-11
FRFR1900284 2019-01-11

Publications (2)

Publication Number Publication Date
WO2020144382A2 WO2020144382A2 (fr) 2020-07-16
WO2020144382A3 true WO2020144382A3 (fr) 2020-09-03

Family

ID=67810644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/050721 WO2020144382A2 (fr) 2019-01-11 2020-01-13 Cellules stromales neonatales felines et leurs utilisations

Country Status (3)

Country Link
US (1) US20220280570A1 (fr)
EP (1) EP3908295A2 (fr)
WO (1) WO2020144382A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117562962B (zh) * 2024-01-15 2024-03-12 四川育强本草生物技术有限公司 美洲大蠊或其提取物的用途及一种治疗猫口炎的中兽药组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120269786A1 (en) * 2010-08-31 2012-10-25 Erik John Woods Systemic, allogenic stem cell therapies for treatment of diseases in felines
WO2015034660A1 (fr) * 2013-09-05 2015-03-12 The Regents Of The University Of California Cellules souches mésenchymateuses pour le traitement d'une inflammation buccale
CN109589403A (zh) * 2018-12-29 2019-04-09 广东维赛生物科技有限公司 一种用于治疗动物肝损伤的干细胞组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062475A1 (fr) 2015-10-05 2017-04-13 The Regents Of The University Of California Utilisation de cellules souches mésenchymateuses pour le traitement de l'inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120269786A1 (en) * 2010-08-31 2012-10-25 Erik John Woods Systemic, allogenic stem cell therapies for treatment of diseases in felines
WO2015034660A1 (fr) * 2013-09-05 2015-03-12 The Regents Of The University Of California Cellules souches mésenchymateuses pour le traitement d'une inflammation buccale
CN109589403A (zh) * 2018-12-29 2019-04-09 广东维赛生物科技有限公司 一种用于治疗动物肝损伤的干细胞组合物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AS VIDANE ET AL: "Transplantation of amniotic membrane-derived multipotent cells ameliorates and delays the progression of chronic kidney disease in cats", REPRODUCTION IN DOMESTIC ANIMALS, vol. 52, 23 October 2016 (2016-10-23), DE, pages 316 - 326, XP055643523, ISSN: 0936-6768, DOI: 10.1111/rda.12846 *
AVERY ET AL: "Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 117, no. 3-4, 10 May 2007 (2007-05-10), pages 222 - 235, XP022068226, ISSN: 0165-2427, DOI: 10.1016/J.VETIMM.2007.02.003 *
BOAZ ARZI ET AL: "Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis", STEM CELLS TRANSLATIONAL MEDICINE, vol. 6, no. 8, 15 June 2017 (2017-06-15), US, pages 1710 - 1722, XP055643643, ISSN: 2157-6564, DOI: 10.1002/sctm.17-0035 *

Also Published As

Publication number Publication date
EP3908295A2 (fr) 2021-11-17
US20220280570A1 (en) 2022-09-08
WO2020144382A2 (fr) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
PH12019502701A1 (en) Atropine pharmaceutical compositions
WO2018049152A8 (fr) Dérivés de pyrazolopyrimidine en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
MX2020010369A (es) Particulas implantables y metodos relacionados.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX362375B (es) Extracto de saliva entera de sanguijuela.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
GEP20247585B (en) Furoindazole derivatives
WO2018201167A3 (fr) Dérivés d'acide propionique et leurs procédés d'utilisation
EP4342473A3 (fr) Composés utiles dans la thérapie du vih
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
MX2022003037A (es) Compuestos antibacterianos.
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
WO2019169333A8 (fr) Composés afibrotiques, dispositifs et leurs utilisations
MX2022007391A (es) Compuestos activos frente a receptores nucleares.
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
WO2020144382A3 (fr) Cellules stromales neonatales felines et leurs utilisations
CA3011003A1 (fr) Fantomes bacteriens pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20700707

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020700707

Country of ref document: EP

Effective date: 20210811